- Home
- ARCT vs GRAL Comparison
ARCT vs GRAL Comparison
Compare ARCT & GRAL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARCT
- GRAL
- Stock Information
- Founded
- ARCT 2013
- GRAL 2016
- Country
- ARCT United States
- GRAL United States
- Employees
- ARCT N/A
- GRAL N/A
- Industry
- ARCT Biotechnology: Pharmaceutical Preparations
- GRAL
- Sector
- ARCT Health Care
- GRAL
- Exchange
- ARCT Nasdaq
- GRAL NYSE
- Market Cap
- ARCT 298.3M
- GRAL 1.6B
- IPO Year
- ARCT N/A
- GRAL N/A
- Fundamental
- Price
- ARCT $13.78
- GRAL $41.07
- Analyst Decision
- ARCT Strong Buy
- GRAL Buy
- Analyst Count
- ARCT 8
- GRAL 3
- Target Price
- ARCT $52.83
- GRAL $31.50
- AVG Volume (30 Days)
- ARCT 484.0K
- GRAL 1.4M
- Earning Date
- ARCT 08-04-2025
- GRAL 08-12-2025
- Dividend Yield
- ARCT N/A
- GRAL N/A
- EPS Growth
- ARCT N/A
- GRAL N/A
- EPS
- ARCT N/A
- GRAL N/A
- Revenue
- ARCT $143,680,000.00
- GRAL $130,711,000.00
- Revenue This Year
- ARCT N/A
- GRAL $19.52
- Revenue Next Year
- ARCT $34.79
- GRAL $20.37
- P/E Ratio
- ARCT N/A
- GRAL N/A
- Revenue Growth
- ARCT 15.38
- GRAL 30.47
- 52 Week Low
- ARCT $8.04
- GRAL $12.33
- 52 Week High
- ARCT $25.88
- GRAL $63.99
- Technical
- Relative Strength Index (RSI)
- ARCT 54.34
- GRAL N/A
- Support Level
- ARCT $13.10
- GRAL N/A
- Resistance Level
- ARCT $15.20
- GRAL N/A
- Average True Range (ATR)
- ARCT 1.02
- GRAL 0.00
- MACD
- ARCT 0.07
- GRAL 0.00
- Stochastic Oscillator
- ARCT 55.21
- GRAL 0.00
About ARCT Arcturus Therapeutics Holdings Inc.
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on opportunities in rare diseases with a current focus on liver and respiratory diseases. It operates in one business segment, which includes all activities related to the discovery, development and commercialization of messenger RNA medicines. The company's pipeline includes LUNAR-OTC, LUNAR-CF, LUNAR-FLU, and LUNAR-COV19.
About GRAL GRAIL INC
GRAIL Inc is a healthcare company focused on developing technologies for early cancer detection. The company has developed a multi-cancer early detection blood test that has the ability to detect all types of cancer, across all stages. It operates in one reportable operating segment which provides multi-cancer early detection testing and service.